Overview

Lorlatinib, supplied as Lorbrexen 100, is a third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 used in ALK-positive non-small-cell lung cancer. Its macrocyclic structure and strong brain penetration make it a distinctive option when disease has moved past earlier ALK inhibitors or into the central nervous system. This article outlines how it is positioned in sequencing and where combination thinking enters the plan. The 100 mg oral tablet is the dose used in the ALK-positive lung cancer pathway.

Sequencing Across ALK-TKI Lines

First- and second-generation ALK inhibitors control disease initially but often select resistance mutations, including the solvent-front G1202R change that limits older agents. Lorlatinib was designed to cover G1202R and to cross the blood-brain barrier, so it is commonly placed after progression on crizotinib or a next-generation ALK inhibitor when a brain or systemic relapse appears. The exact line of use depends on prior therapy, the resistance pattern, and the patient's tolerance. CNS imaging alongside plasma genotyping helps decide whether the drug is the right next line.

Combination and Supportive Logic

In routine practice lorlatinib is used sequentially rather than combined with another ALK inhibitor, since layering two ALK blockers rarely helps and adds toxicity. Combination thinking instead appears in trials pairing it with chemotherapy or immunotherapy, and in managing central-nervous-system disease where its penetration is an advantage. Procurement teams should track the resistance-test result and the intended line, because pack planning follows the treating center's sequencing protocol. Toxicity monitoring stays important because CNS-active and combined regimens carry their own safety profile. Documented resistance results and the intended line should both be recorded so replenishment matches the clinic's actual sequencing need. Sharing the sequencing plan with the supplier smooths replenishment when the next treatment line is activated.

FAQ

Q: Why is brain penetration emphasized for this drug? A: ALK-positive disease often relapses in the brain; lorlatinib crosses the blood-brain barrier, which matters when CNS lesions appear after earlier inhibitors.

Q: What is the G1202R mutation and why does it matter? A: It is a solvent-front ALK resistance change that undermines older ALK inhibitors; lorlatinib was designed to remain active against it.

Q: Is lorlatinib combined with other ALK drugs? A: Generally no. It is sequenced after other ALK inhibitors rather than stacked with them, with combination use mainly in clinical trials.